In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
The in vitro activity of moxifloxacin against 923 recent anaerobic isolates obtained from pretreatment cultures in patients with complicated intra-abdominal infections was studied using the CLSI M11-A-6 agar dilution method. Moxifloxacin was active against 87% (96 of 110) Bacteroides fragilis strains at < or = 1 microg/ml and 87% (79 of 90) B. thetaiotaomicron strains at < or = 2 microg/ml. Species variation was seen, with B. uniformis, B. vulgatus, Clostridium clostridioforme, and C. symbiosum being least susceptible and accounting for most of the resistant isolates; excluding the aforementioned four resistant species, 86% (303 of 363) of Bacteroides species isolates and 94% (417 of 450) of all other genera and species were susceptible to < or = 2 microg/ml of moxifloxacin. Overall, moxifloxacin was active against 763 of 923 (83%) of strains at < or = 2 microg/ml, supporting its use as a monotherapy for some community-acquired intra-abdominal infections.
Goldstein
Ellie J C
EJ
R. M. Alden Research Laboratory, 2021 Santa Monica Blvd., Suite #740 East, Santa Monica, California 90404, USA. ejcgmd@aol.com
Citron
Diane M
DM
Warren
Yumi A
YA
Tyrrell
Kerin L
KL
Merriam
C Vreni
CV
Fernandez
Helen
H
D001372:Aza Compounds / Q000494:pharmacology*; D001442:Bacteroides Infections / Q000453:epidemiology; D001441:Bacteroides fragilis / Q000187:drug effects / Q000302:isolation & purification*; D024841:Fluoroquinolones; D006089:Gram-Negative Anaerobic Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011804:Quinolines / Q000494:pharmacology*; D013272:Stomach Diseases / Q000382:microbiology*
D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin